Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Patients With Hereditary Periodic Fevers
jRCT2080222483Phase 3
- Sponsor
- Novartis
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoinflammatory dermatological diseases (SAIDs) comparing Canakinumab arm with Placebo arm (2 arms). Primary endpoint: Primary efficacy and safety outcomes.
02
Drugs
canakinumab
03
Conditions
autoinflammatory dermatological diseases (SAIDs)
Beyond the preview
Go deeper on jRCT2080222483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222483.